JP2019513779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513779A5 JP2019513779A5 JP2018553928A JP2018553928A JP2019513779A5 JP 2019513779 A5 JP2019513779 A5 JP 2019513779A5 JP 2018553928 A JP2018553928 A JP 2018553928A JP 2018553928 A JP2018553928 A JP 2018553928A JP 2019513779 A5 JP2019513779 A5 JP 2019513779A5
- Authority
- JP
- Japan
- Prior art keywords
- aav vector
- seq
- recombinant aav
- nucleotide sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013607 AAV vector Substances 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 55
- 239000002773 nucleotide Substances 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 50
- 210000003205 muscle Anatomy 0.000 claims description 36
- 108091047189 miR-29c stem-loop Proteins 0.000 claims description 34
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims description 34
- 102000001039 Dystrophin Human genes 0.000 claims description 21
- 108010069091 Dystrophin Proteins 0.000 claims description 21
- 201000006938 muscular dystrophy Diseases 0.000 claims description 21
- 206010016654 Fibrosis Diseases 0.000 claims description 15
- 230000004761 fibrosis Effects 0.000 claims description 15
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 238000007910 systemic administration Methods 0.000 claims description 7
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 5
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 5
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 5
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 5
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 5
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 5
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 5
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 5
- 241000300529 Adeno-associated virus 13 Species 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000005856 abnormality Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 11
- 108091007431 miR-29 Proteins 0.000 description 4
- 239000013608 rAAV vector Substances 0.000 description 4
- 108091029162 miR-29 stem-loop Proteins 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323163P | 2016-04-15 | 2016-04-15 | |
| US62/323,163 | 2016-04-15 | ||
| US201762473253P | 2017-03-17 | 2017-03-17 | |
| US62/473,253 | 2017-03-17 | ||
| PCT/US2017/027635 WO2017181014A1 (en) | 2016-04-15 | 2017-04-14 | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513779A JP2019513779A (ja) | 2019-05-30 |
| JP2019513779A5 true JP2019513779A5 (enExample) | 2020-05-28 |
| JP7189771B2 JP7189771B2 (ja) | 2022-12-14 |
Family
ID=60041940
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553882A Active JP7153562B2 (ja) | 2016-04-15 | 2017-04-14 | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９のアデノ随伴ウイルスベクター送達 |
| JP2018553951A Active JP7078546B2 (ja) | 2016-04-15 | 2017-04-14 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2018553928A Active JP7189771B2 (ja) | 2016-04-15 | 2017-04-14 | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９およびマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2021190072A Active JP7431789B2 (ja) | 2016-04-15 | 2021-11-24 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2023201579A Active JP7833440B2 (ja) | 2016-04-15 | 2023-11-29 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2025075669A Pending JP2025118741A (ja) | 2016-04-15 | 2025-04-30 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553882A Active JP7153562B2 (ja) | 2016-04-15 | 2017-04-14 | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９のアデノ随伴ウイルスベクター送達 |
| JP2018553951A Active JP7078546B2 (ja) | 2016-04-15 | 2017-04-14 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021190072A Active JP7431789B2 (ja) | 2016-04-15 | 2021-11-24 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2023201579A Active JP7833440B2 (ja) | 2016-04-15 | 2023-11-29 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| JP2025075669A Pending JP2025118741A (ja) | 2016-04-15 | 2025-04-30 | 筋ジストロフィーを治療するためのマイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US11298429B2 (enExample) |
| EP (5) | EP3442561B1 (enExample) |
| JP (6) | JP7153562B2 (enExample) |
| KR (3) | KR102649707B1 (enExample) |
| CN (2) | CN109069672B (enExample) |
| AU (4) | AU2017250790B2 (enExample) |
| CA (2) | CA3020996A1 (enExample) |
| CO (1) | CO2018012084A2 (enExample) |
| DK (1) | DK3442602T3 (enExample) |
| ES (3) | ES2977730T3 (enExample) |
| FI (1) | FI3442602T3 (enExample) |
| HR (1) | HRP20250541T1 (enExample) |
| HU (1) | HUE071243T2 (enExample) |
| IL (3) | IL262194B2 (enExample) |
| LT (1) | LT3442602T (enExample) |
| MA (2) | MA44683B1 (enExample) |
| MD (1) | MD3442602T2 (enExample) |
| MX (2) | MX2018012604A (enExample) |
| MY (2) | MY195438A (enExample) |
| NZ (2) | NZ787316A (enExample) |
| PL (1) | PL3442602T3 (enExample) |
| PT (1) | PT3442602T (enExample) |
| RS (1) | RS66847B1 (enExample) |
| SG (1) | SG11201808941PA (enExample) |
| SI (1) | SI3442602T1 (enExample) |
| WO (3) | WO2017181011A1 (enExample) |
| ZA (2) | ZA201806746B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11617783B2 (en) | 2015-11-16 | 2023-04-04 | Research Institute At Nationwide Children's Hospital | Repairing a mutant human titin gene using CRISPR technology |
| JP7153562B2 (ja) | 2016-04-15 | 2022-10-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９のアデノ随伴ウイルスベクター送達 |
| DK3596222T5 (da) * | 2017-03-17 | 2024-09-02 | Res Inst Nationwide Childrens Hospital | Adenoassocieret virusvektorfremføring af muskelspecifik mikro-dystrophin til behandling af muskeldystrofi |
| WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY |
| JP7213238B2 (ja) * | 2017-10-18 | 2023-01-26 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達 |
| CN111433367A (zh) * | 2017-10-20 | 2020-07-17 | 全国儿童医院研究所 | Nt-3基因疗法的方法和材料 |
| AU2019216257B2 (en) | 2018-01-31 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for limb-girdle muscular dystrophy type 2C |
| WO2019178412A1 (en) * | 2018-03-16 | 2019-09-19 | Research Institute At Nationwide Children's Hospital | Increasing tissue specific gene delivery by capsid modification |
| EP3796919A4 (en) * | 2018-05-15 | 2022-02-16 | Ramot at Tel-Aviv University Ltd. | MIR126-5P FOR THE TREATMENT OF MOTOR NEURON DISEASES |
| EP4591888A3 (en) * | 2018-06-18 | 2026-01-21 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| CA3104471A1 (en) * | 2018-06-18 | 2019-12-26 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies |
| US12391928B2 (en) | 2018-06-29 | 2025-08-19 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A |
| EP3598978B1 (en) | 2018-07-26 | 2024-05-29 | EXOFIX S.r.l. | Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles |
| AU2019395388A1 (en) * | 2018-12-12 | 2021-07-29 | Solid Biosciences Inc. | Combination therapy for treating muscular dystrophy |
| CN113766935A (zh) | 2019-02-26 | 2021-12-07 | 全国儿童医院研究所 | β-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗 |
| JP7635139B2 (ja) * | 2019-03-25 | 2025-02-25 | ジェネトン | オーバーラップａａｖベクターを使用する大きいサイズのクアシジストロフィンの産生 |
| SI4017871T1 (sl) | 2019-08-21 | 2024-06-28 | Research Institute At Nationwide Children's Hospital | Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije |
| JP2023510799A (ja) * | 2020-01-10 | 2023-03-15 | ソリッド・バイオサイエンシーズ・インコーポレーテッド | 併用療法のためのウイルスベクター |
| WO2021142435A1 (en) * | 2020-01-10 | 2021-07-15 | Solid Biosciences Inc. | Combination therapy for treating muscular dystrophy |
| WO2021222332A1 (en) | 2020-04-29 | 2021-11-04 | Bristol-Myers Squibb Company | Miniaturized dystrophins having spectrin fusion domains and uses thereof |
| JP2023530974A (ja) * | 2020-06-15 | 2023-07-20 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーのためのアデノ随伴ウイルスベクター送達 |
| CN111733185A (zh) * | 2020-06-30 | 2020-10-02 | 华南农业大学 | 通过Mdfi基因编辑来实现动物肉品质改良的方法和应用 |
| EP3936616A1 (en) * | 2020-07-10 | 2022-01-12 | Charité - Universitätsmedizin Berlin | Microrna-targeted therapy for cardiac repair |
| IL310725A (en) | 2021-08-11 | 2024-04-01 | Solid Biosciences Inc | Treatment of muscular dystrophy |
| WO2023044441A1 (en) * | 2021-09-16 | 2023-03-23 | University Of Florida Research Foundation, Incorporated | Aav particles with modified inverted terminal repeats for enhanced gene expression in muscle |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| CN115819546B (zh) * | 2022-08-19 | 2025-12-05 | 成都金唯科生物科技有限公司 | 表达微缩抗肌营养不良蛋白基因的腺相关病毒载体及其应用 |
| US20260055144A1 (en) | 2022-08-24 | 2026-02-26 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
| US20250276095A1 (en) * | 2024-03-04 | 2025-09-04 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy |
| WO2026011009A1 (en) * | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
| WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| AU722196B2 (en) | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
| CA2230758A1 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
| US5795872A (en) | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| CN1233291A (zh) | 1996-09-06 | 1999-10-27 | 宾西法尼亚大学托管会 | 重组腺伴随病毒定向基因治疗的方法 |
| WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| JPH11318467A (ja) | 1998-05-08 | 1999-11-24 | Japan Science & Technology Corp | 短縮型ジストロフィン |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| WO2001083695A2 (en) | 2000-04-28 | 2001-11-08 | Xiao Xiao | Dna sequences encoding dystrophin minigenes and methods of use thereof |
| ATE373095T1 (de) | 2000-07-14 | 2007-09-15 | Univ Michigan | Mutierte muskelspezifische enhancer |
| DE60134786D1 (de) | 2000-10-06 | 2008-08-21 | Univ Michigan | Mini-dystrophin nukleinsäure- und peptidsequenzen |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
| WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| US20080044393A1 (en) | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| US8440636B2 (en) | 2007-07-31 | 2013-05-14 | The Board Of Regents, The University Of Texas System | Micro-RNA family that modulates fibrosis and uses thereof |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| WO2010071454A1 (en) * | 2008-12-17 | 2010-06-24 | Auckland Uniservices Limited | Adeno-associated viral vectors and uses thereof |
| CA2842798C (en) | 2011-07-25 | 2021-02-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| WO2013075008A1 (en) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| JP2015503924A (ja) | 2012-01-05 | 2015-02-05 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 遺伝子導入のための方法及び組成物 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| US9624282B2 (en) | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
| EP2986632B1 (en) * | 2013-04-20 | 2018-09-05 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
| WO2015110449A1 (en) | 2014-01-21 | 2015-07-30 | Vrije Universiteit Brussel | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| WO2015157306A1 (en) | 2014-04-09 | 2015-10-15 | University Of Houston | Therapeutic mirnas for treating heart and skeletal muscle diseases |
| US10119140B2 (en) | 2014-04-18 | 2018-11-06 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy |
| EP2960336A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
| JP6986444B2 (ja) * | 2014-08-09 | 2021-12-22 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｄｍｄ遺伝子のエクソン５内の内部リボソーム進入部位を活性化するための方法及び材料 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| WO2016057975A2 (en) * | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
| US10479821B2 (en) | 2015-01-16 | 2019-11-19 | University Of Washington | Micro-dystrophins and related methods of use |
| GB201507842D0 (en) | 2015-05-07 | 2015-06-17 | New Royal Holloway & Bedford | Production of large-sized microdystrophins in an AAV-based vector configuration |
| EA201890543A1 (ru) | 2015-09-17 | 2018-08-31 | Рисёрч Инститьют Эт Нэйшнвайд Чилдрен'С Хоспитэл | Способы и материалы для генной терапии galgt2 |
| WO2017165859A1 (en) | 2016-03-24 | 2017-09-28 | Research Institute At Nationwide Children's Hospital | Modified viral capsid proteins |
| JP7153562B2 (ja) | 2016-04-15 | 2022-10-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 筋ジストロフィーを治療するためのマイクロｒｎａ－２９のアデノ随伴ウイルスベクター送達 |
| PL3442600T3 (pl) * | 2016-04-15 | 2024-07-08 | Research Institute At Nationwide Children's Hospital | Dostarczanie za pośrednictwem wirusa związanego z adenowirusem wektora b- sarkoglikanu i mikroRNA-29 oraz leczenie dystrofii mięśniowej |
| RU2753194C2 (ru) | 2016-06-21 | 2021-08-12 | Бамбу Терапьютикс, Инк. | Оптимизированные гены и экспрессионные кассеты мини-дистрофина и их применение |
| EP4591888A3 (en) | 2018-06-18 | 2026-01-21 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
-
2017
- 2017-04-14 JP JP2018553882A patent/JP7153562B2/ja active Active
- 2017-04-14 PT PT177832367T patent/PT3442602T/pt unknown
- 2017-04-14 ES ES17783235T patent/ES2977730T3/es active Active
- 2017-04-14 MX MX2018012604A patent/MX2018012604A/es unknown
- 2017-04-14 NZ NZ787316A patent/NZ787316A/en unknown
- 2017-04-14 RS RS20250432A patent/RS66847B1/sr unknown
- 2017-04-14 SI SI201731603T patent/SI3442602T1/sl unknown
- 2017-04-14 FI FIEP17783236.7T patent/FI3442602T3/fi active
- 2017-04-14 CA CA3020996A patent/CA3020996A1/en active Pending
- 2017-04-14 JP JP2018553951A patent/JP7078546B2/ja active Active
- 2017-04-14 EP EP17783235.9A patent/EP3442561B1/en active Active
- 2017-04-14 AU AU2017250790A patent/AU2017250790B2/en active Active
- 2017-04-14 WO PCT/US2017/027630 patent/WO2017181011A1/en not_active Ceased
- 2017-04-14 LT LTEPPCT/US2017/027636T patent/LT3442602T/lt unknown
- 2017-04-14 MA MA44683A patent/MA44683B1/fr unknown
- 2017-04-14 NZ NZ747049A patent/NZ747049A/en unknown
- 2017-04-14 PL PL17783236.7T patent/PL3442602T3/pl unknown
- 2017-04-14 WO PCT/US2017/027635 patent/WO2017181014A1/en not_active Ceased
- 2017-04-14 CA CA3020999A patent/CA3020999A1/en active Pending
- 2017-04-14 HU HUE17783236A patent/HUE071243T2/hu unknown
- 2017-04-14 JP JP2018553928A patent/JP7189771B2/ja active Active
- 2017-04-14 MY MYPI2018001733A patent/MY195438A/en unknown
- 2017-04-14 IL IL262194A patent/IL262194B2/en unknown
- 2017-04-14 DK DK17783236.7T patent/DK3442602T3/da active
- 2017-04-14 CN CN201780023711.2A patent/CN109069672B/zh active Active
- 2017-04-14 EP EP25158662.4A patent/EP4541894A3/en active Pending
- 2017-04-14 IL IL319636A patent/IL319636A/en unknown
- 2017-04-14 KR KR1020187032687A patent/KR102649707B1/ko active Active
- 2017-04-14 KR KR1020247008867A patent/KR102801562B1/ko active Active
- 2017-04-14 US US16/092,711 patent/US11298429B2/en active Active
- 2017-04-14 EP EP17783232.6A patent/EP3442601B1/en active Active
- 2017-04-14 ES ES17783236T patent/ES3026989T3/es active Active
- 2017-04-14 HR HRP20250541TT patent/HRP20250541T1/hr unknown
- 2017-04-14 MY MYPI2022005940A patent/MY209041A/en unknown
- 2017-04-14 AU AU2017250791A patent/AU2017250791B2/en active Active
- 2017-04-14 KR KR1020257013509A patent/KR20250061772A/ko active Pending
- 2017-04-14 IL IL302200A patent/IL302200B2/en unknown
- 2017-04-14 SG SG11201808941PA patent/SG11201808941PA/en unknown
- 2017-04-14 EP EP24157430.0A patent/EP4410979A3/en active Pending
- 2017-04-14 MD MDE20190237T patent/MD3442602T2/ro unknown
- 2017-04-14 WO PCT/US2017/027636 patent/WO2017181015A1/en not_active Ceased
- 2017-04-14 US US16/092,706 patent/US11406717B2/en active Active
- 2017-04-14 CN CN202410708447.8A patent/CN118895311A/zh active Pending
- 2017-04-14 ES ES17783232T patent/ES2985822T3/es active Active
- 2017-04-14 US US16/093,022 patent/US11723986B2/en active Active
- 2017-04-14 MA MA045477A patent/MA45477A/fr unknown
- 2017-04-14 EP EP17783236.7A patent/EP3442602B1/en active Active
-
2018
- 2018-10-10 ZA ZA2018/06746A patent/ZA201806746B/en unknown
- 2018-10-15 MX MX2024005644A patent/MX2024005644A/es unknown
- 2018-11-08 CO CONC2018/0012084A patent/CO2018012084A2/es unknown
-
2019
- 2019-10-08 ZA ZA2019/06608A patent/ZA201906608B/en unknown
-
2021
- 2021-11-24 JP JP2021190072A patent/JP7431789B2/ja active Active
-
2022
- 2022-04-12 US US17/719,019 patent/US20230001015A1/en not_active Abandoned
- 2022-06-10 US US17/837,821 patent/US20230173101A1/en not_active Abandoned
-
2023
- 2023-02-23 AU AU2023201093A patent/AU2023201093B2/en active Active
- 2023-11-29 JP JP2023201579A patent/JP7833440B2/ja active Active
-
2024
- 2024-10-03 US US18/906,008 patent/US20250161490A1/en active Pending
-
2025
- 2025-04-30 JP JP2025075669A patent/JP2025118741A/ja active Pending
- 2025-07-24 AU AU2025208472A patent/AU2025208472A1/en active Pending
- 2025-08-13 US US19/298,798 patent/US20260027235A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513779A5 (enExample) | ||
| JP2019513393A5 (enExample) | ||
| JP2020513811A5 (enExample) | ||
| JP2019513389A5 (enExample) | ||
| JP2021500352A5 (enExample) | ||
| JP2019513399A5 (enExample) | ||
| FI3596222T3 (fi) | Lihasspesifisen mikrodystrofiinin adenoassosioitu virusvektori -kuljetus lihasdystrofian hoitamiseksi | |
| JP2020510447A5 (enExample) | ||
| FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
| FI3442600T3 (fi) | Adeno-assosioidulla virusvektorilla b-sarkoglykaanin ja mikro-rna-29:n toimittaminen ja lihasdystrofian hoito | |
| HRP20250897T1 (hr) | Genska terapija za neurodegenerativne poremećaje | |
| FI2212424T4 (fi) | Laaja-alainen geenien vienti motoneuroneihin AAV-vektorien periferaalista injektiota käyttäen | |
| IL320714A (en) | Gene therapy for limb-girdle muscular dystrophy type 2c | |
| WO2016077687A4 (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| JP2020514286A5 (enExample) | ||
| JP2019511570A5 (enExample) | ||
| JP2020510428A5 (enExample) | ||
| EP2933335A1 (en) | A method of treating peripheral neuropathies and motor neuron diseases | |
| JP2023528580A (ja) | 筋肉及び中枢神経系障害の遺伝子治療のための合成ａａｖカプシドの使用 | |
| JP2018510620A5 (enExample) | ||
| JP2017529395A5 (enExample) | ||
| JP2019515663A5 (enExample) | ||
| RU2018121289A (ru) | Способы лечения мышечной дистрофии | |
| JPWO2019152474A5 (enExample) | ||
| JP2018538261A5 (enExample) |